Compare
Maravai Lifesciences Holdings, Inc. vs Stoke Therapeutics, Inc. vs Lifevantage Corp vs Rhythm Pharmaceuticals, Inc.
| Latest fiscal year | Maravai Lifesciences Holdings, Inc. MRVI | Stoke Therapeutics, Inc. STOK | Lifevantage Corp LFVN | Rhythm Pharmaceuticals, Inc. RYTM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $185.74M | $184.42M | $182.59M | $189.76M |
| Revenue growth (YoY) | -28.3% | +404.5% | -20.1% | +45.8% |
| Gross margin | 18.3% | n/a | 77.6% | 89.7% (computed) |
| Operating margin | -115.9% | -11.2% | 3.3% | -101.2% |
| Net margin | -70.4% | -3.7% | 2.8% | -103.6% |
| Net income | -$130.77M | -$6.88M | $5.07M | -$196.54M |
| EPS (Diluted) | -$0.90 | -$0.12 | $0.40 | -$3.11 |
| Operating cash flow | -$57.57M | $45.59M | $10.24M | -$115.67M |
| Free cash flow | -$70.72M | $44.91M | $6.67M | -$116.63M |
| Cash & equivalents | $216.89M | $84.22M | n/a | $54.30M |
| Total assets | $770.58M | $418.43M | $62.11M | $480.20M |
| Total liabilities | $397.87M | $65.98M | $28.52M | $210.17M |
| Shareholders' equity | $212.38M | $352.46M | $33.59M | $139.07M |
| Return on year-end equity | -61.6% | -2.0% | 15.1% | -141.3% |
| Shares outstanding | n/a | 58.92M | 12.52M | 67.21M |
Revenue, most recent five fiscal years
| Fiscal year | Maravai Lifesciences Holdings, Inc. | Stoke Therapeutics, Inc. | Lifevantage Corp | Rhythm Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $185.74M Ended 2025-12-31 | $184.42M Ended 2025-12-31 | $182.59M Ended 2026-06-30 | $189.76M Ended 2025-12-31 |
| 1 year earlier | $259.19M Ended 2024-12-31 | $36.55M Ended 2024-12-31 | $228.53M Ended 2025-06-30 | $130.13M Ended 2024-12-31 |
| 2 years earlier | $288.94M Ended 2023-12-31 | $8.78M Ended 2023-12-31 | $200.16M Ended 2024-06-30 | $77.43M Ended 2023-12-31 |
| 3 years earlier | $883.00M Ended 2022-12-31 | $12.40M Ended 2022-12-31 | $213.40M Ended 2023-06-30 | $23.64M Ended 2022-12-31 |
| 4 years earlier | $799.24M Ended 2021-12-31 | n/a | $206.36M Ended 2022-06-30 | $3.15M Ended 2021-12-31 |